造血干细胞移植受者环孢素A血药浓度监测指标研究

目的:探讨造血干细胞移植受者环孢素A(CsA)理想的血药浓度监测指标。方法:采用荧光偏振免疫(FPIA)法,对23例造血干细胞移植受者进行全血中CsA谷浓度(C0)及服药后2h血药浓度(C2)进行监测,并对数据进行归纳分析。结果:造血干细胞移植术后6月内C0平均值为(228·84±142·48)μg·L-1,C2平均值为(741·50±294·42)μg·L-1,C0+C2平均值为(970·34±391·18)μg·L-1,C2/C0平均值为(3·88±1·94)μg·L-1。结论:C0+C2和C2/C0作为CsA血药浓度监测指标合理,更能全面反映CsA体内药物暴露情况,并能监测CsA肝、肾毒性。

Monitoring Indexes of Plasma CsA Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation

OBJECTIVE： To study the optimal monitoring indexes of plasma concentration of cyclosporine A （CsA） in patients receiving hematopoietic stem cell transplantation. METHODS： The lowest CsA concentration （C0） and the highest CsA concentration （C2） in 23 hematopoietic stem cell transplant recipients were detected by FPIA. All the data were analyzed statistically. RESULTS： Within 6 months after hematopoietic stem cell transplanttion, C0, C2, C0＋ C2 and C2/C0 in the recipients were （228.84±142.48） μg·L^-1, （741.50±294.42） μg·L^-1, （970.34±391.18） μg·L^-1 and （3.88±1.94） μg·L^-1, respectively. CONCLUSION ： As reasonable monitoring indexes for the plasma concentration of CsA, C0＋ C2 and C2/C0 can comprehensively reflect the exposure of drug in body and monitor the toxicity of CsA in liver and kidney.